The treatment of non-Hodgkin’s lymphoma
(NHL) continues to be imperfect. With incidence increasing and the chance of
cure at less than 50%, an improved understanding of NHL is needed, including
which patients will benefit most from various treatments. The American Cancer
Society estimates that 53,900 new cases of NHL will be diagnosed in 2002, and
24,400 related deaths will occur. Both the incidence and mortality of NHL have
been rising since the 1970s. Overall, survival rates are suboptimal, with 1-year
survivals of 70% and 5-year survivals of only 51%.[2,3]
The ongoing effort to better understand NHL is reflected by the
multiple modifications made to NHL classification systems over the past
2 decades. The World Health Organization (WHO) classification system is the
most recently developed and is in line to replace the existing Working
Formulation and Kiel classification systems.[4,5] The WHO classification
reflects improvements in the understanding of the immune system, and is based on
several factors, including histology, immune phenotype, genetic abnormalities,
and clinical features.
Mitoxantrone (Novantrone) is a cytotoxic anthracenedione,
similar in structure to anthracyclines such as doxorubicin. It inhibits
interferes with RNA, and intercalates with DNA (resulting in strand breaks and
cross-links)all of which lead to cell death. Mitoxantrone is not cell-cycle
specific.[6,7] It was developed in the 1970s as a more tolerable alternative to
anthracyclines. Early research established its activity alone and in
combination with other chemotherapy agents against breast cancer, leukemia, and
lymphoma. More recent studies have demonstrated its activity in the treatment of
prostate cancer and in slowing the progression of multiple sclerosis.[7,8]
Specifically, the activity of mitoxantrone has been established
against both follicular lymphomas and aggressive lymphomas, including diffuse
large-cell lymphomas. In preliminary studies of follicular lymphoma,
mitoxantrone at 14 to 18 mg/m² every 3 to 4 weeks yielded responses in
previously treated patients (including those who had received doxorubicin), with
complete response rates ranging from 6% to 16% and partial response rates from
38% to 56%.[9-11] Previously untreated patients with follicular lymphoma had
slightly higher response rates, with a complete response rate of 29% and a
partial response rate of 67%.
Patients with relapsed or refractory aggressive lymphoma
responded to lower doses of mitoxantrone (12 to 14 mg/m² every 3 to 4 weeks).
The complete response rate ranged from 0% to 30% and the partial response rate,
from 12% to 63%. Some of these patients had received previous treatment with
doxorubicin.[9,10,13-16] This review will evaluate the current use of
mitoxantrone in NHL, paying special attention to dose as it relates to outcome.
Determining the optimal dose of mitoxantrone in NHL leads to a
related question: What is the comparable dose of mitoxantrone and doxorubicin
for use in NHL? The relevance of the question stems from the widespread use of
doxorubicin in combination therapy for NHL, the high level of activity of both
doxorubicin and mitoxantrone in NHL, and the fact that mitoxantrone is closely
related to the anthracyclines pharmacologically.
Posner et al reported that in early comparative trials of
mitoxantrone and doxorubicin in breast cancer, a 5:1 ratio of doxorubicin to
mitoxantrone was chosen based on data suggesting that this ratio would yield
equally myelosuppressive doses of the drugs. Thus, when comparing CNF
(cyclophosphamide [Cytoxan, Neosar], mitoxantrone [Novantrone], fluorouracil
[5-FU]) to CAF (cyclophosphamide, doxorubicin [Adriamycin], 5-FU) in breast
cancer, 10 mg/m² of mitoxantrone was compared to 50 mg/m² of doxorubicin.
Single-agent comparisons used 12 to 14 mg/m² of mitoxantrone and 60 to 75 mg/m²
of doxorubicin administered every 3 to 4 weeks.
As described later in this review, the doses of mitoxantrone in
combination therapy for NHL have ranged from 10 to 12 mg/m². Given that 12 mg/m²
represents a 20% increase in dose intensity over the lower dose, an increase of
2 mg/m² could be an extremely important difference if there is a significant
dose-response curve at this dose range.
Moderate reductions in the dose intensity of doxorubicin have
produced a striking decrease in treatment outcome for breast cancer
patients. In the treatment of aggressive NHL, two studies found that 50 mg/m² of doxorubicin in the CHOP regimen (cyclophosphamide, doxorubicin HCl,
vincristine, prednisone) was superior to 10 mg/m² of mitoxantrone in CNOP
(cyclophosphamide, mitoxantrone, vincristine, prednisone),[19,20] and one study
found the two regimens to be comparable.
In a fourth trial, CNOP was found to be comparable to CHOP when
the dose of mitoxantrone was increased to 12 mg/m² and compared to 50 mg/m²
doxorubicin. Similar results were observed in other regimens that
substituted mitoxantrone, 12 mg/m², for doxorubicin, 50 mg/m², or
mitoxantrone, 10 mg/m², for doxorubicin, 45 mg/m².[24,25] Therefore,
the CNOP regimen should include mitoxantrone at 12 mg/m² if the goal is to
achieve a therapeutic outcome comparable to that of CHOP with doxorubicin at 50
Patients receiving mitoxantrone experience less nonhematologic
toxicity (alopecia, nausea, vomiting) than those receiving doxorubicin. This
advantage may be particularly beneficial to patients such as the elderly, who
may not tolerate full-dose doxorubicin therapy.
In early trials comparing mitoxantrone to doxorubicin (or CAF to
CNF) in breast cancer, significantly lower rates of alopecia, nausea, vomiting,
and stomatitis were reported in the mitoxantrone arm. In later trials in
lymphoma patients, in which a mitoxantrone-containing regimen was compared to a
doxorubicin-containing regimen, the severity of alopecia was significantly
reduced in many studies[19,20,22-26] or reported to occur less
frequently.[21,27] Similarly, nausea and vomiting were significantly reduced in
trials comparing a mitoxantrone regimen to a doxorubicin regimen,[19,20] with
one trial reporting significantly less mucositis in the mitoxantrone arm.
Studies have shown that the cardiotoxicity associated with
mitoxantrone is qualitatively similar to that associated with the anthracyclines,
and is more likely to appear after cumulative mitoxantrone doses of 160 mg/m²,
or 100 mg/m² if the patient has received previous anthracycline
therapy. Although mitoxantrone may be less cardiotoxic than doxorubicin at
comparable cumulative doses, caution is necessary because cardiotoxicity can
also occur at low doses of mitoxantrone. Patients who have previously received
doxorubicin or mediastinal irradiation, or who have underlying cardiac disease,
will be at greater risk for mitoxantrone-associated cardiotoxicity.[6,7]
1. Hauke RJ, Armitage JO: Treatment of non-Hodgkin’s lymphoma.
Curr Opin Oncol 12:412-418, 2000.
2. Surveillance Epidemiology and End Results (SEER) Program of
the National Cancer Institute: SEER Cancer Statistics Review 1973-1998.
Available at http://www.seer.cancer.gov/publications. Accessed February 26,
3. Cancer Facts and Figures 2002: Selected Cancers: Lymphoma.
Available at http://www.cancer.org. Accessed February 26, 2002.
4. Armitage J, Weisenburger D: New approach to classifying
non-Hodgkin’s lymphomas: Clinical features of the major histologic subtypes.
Non-Hodgkin’s Lymphoma Classification Project. J Clin Oncol 16:2780-2795,
5. Longo D: Lymphomas: Complexity, not chaos. Curr Opin Oncol
6. Faulds D, Balfour JA, Chrisp P, et al: Mitoxantrone: A review
of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential
in the chemotherapy of cancer. Drugs 41:400-449, 1991.
7. Immunex Corporation: Novantrone (mitoxantrone for injection
concentrate) package insert. Seattle, 1997.
8. Ehninger G, Schuler U, Proksch B, et al: Pharmacokinetics and
metabolism of mitoxantrone. A review. Clin Pharmacokinet 18:365-380, 1990.
9. Foss-Abrahamsen A, Lenner P, Hedenus M, et al: Mitoxantrone
in the treatment of patients with non-Hodgkin’s Lymphoma. Cancer Treat Rep
10. Silver RT, Case DC Jr, Wheeler RH, et al: Multicenter
clinical trial of mitoxantrone in non-Hodgkin’s lymphoma and Hodgkin’s
disease. J Clin Oncol 9:754-761, 1991.
11. Angelopoulou MK, Lafioniatis SN, Pangalis GA: Low-grade
non-Hodgkin’s lymphomas: Disease control with mitoxanthrone monotherapy in
patients refractory to conventional therapy. Leuk Lymphoma 12:253-257, 1994.
12. Hansen SW, Nissen NI, Hansen MM, et al: High activity of
mitoxantrone in previously untreated low-grade lymphomas. Cancer Chemother
Pharmacol 22:77-79, 1988.
13. Coltman CA Jr, McDaniel TM, Balcerzak SP, et al:
Mitoxantrone hydrochloride in lymphoma. Cancer Treat Rev 10(suppl B):73-76,
14. Gams RA, Keller JW, Golomb HM, et al: Mitoxantrone in
malignant lymphomas. Cancer Treat Rev 10(suppl B):69-72, 1983.
15. Bajetta E, Buzzoni R, Valagussa P, et al: Mitoxantrone: An
active agent in refractory non-Hodgkin’s lymphomas. Am J Clin Oncol
16. Chisesi T: The rationale of therapy with mitoxantrone in
non-Hodgkin’s lymphoma. The Non-Hodgkin’s Lymphoma Cooperative Study Group,
(NHLCSG) Italy. Leuk Lymphoma 9:63-69, 1993.
17. Posner LE, Dukart G, Goldberg J, et al: Mitoxantrone: An
overview of safety and toxicity. Invest New Drugs 3:123-132, 1985.
18. Wood WC, Budman DR, Korzun AH, et al: Dose and dose
intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma.
N Engl J Med 330:1253-1259, 1994.
19. Bezwoda W, Rastogi RB, Erazo Valla A, et al: Long-term
results of a multicentre randomised, comparative phase III trial of CHOP vs CNOP
regimens in patients with intermediate- and high-grade non-Hodgkin’s
lymphomas. Novantrone International Study Group. Eur J Cancer 31A:903-911, 1995.
20. Sonneveld P, de Ridder M, van der Lelie H, et al: Comparison
of doxorubicin and mitoxantrone in the treatment of elderly patients with
advanced diffuse non-Hodgkin’s lymphoma using CHOP vs CNOP chemotherapy. J
Clin Oncol 13:2530-2539, 1995.
21. Pavlovsky S, Santarelli MT, Erazo A, et al: Results of a
randomized study of previously-untreated intermediate and high-grade lymphoma
using CHOP vs CNOP. Ann Oncol 3:205-209, 1992.
22. Brusamolino E, Bertini M, Guidi S: CHOP vs CNOP (N =
mitoxantrone) in non-Hodgkin’s lymphoma: An interim report comparing efficacy
and toxicity. Haematologica 73:217-222, 1988.
23. Vose JM, Anderson JR, Bierman PJ et al: Comparison of
front-line chemotherapy for aggressive non-Hodgkin’s lymphoma using the
CAP-BOP regimens. The Nebraska Lymphoma Study Group. Semin Hematol 31:4-8, 1994.
24. Case D, Wolff S, Bennett J et al: Phase III comparative
trial of M-B-Adriamycin COD (M-BACOD) vs M-B-Novantrone COD (M-BNCOD) in the
treatment of intermediate/high-grade lymphoma. Blood 72 (suppl 1):239a, 1988.
25. Guglielmi C, Gherlinzoni F, Amadori S, et al: A phase III
comparative trial of m-BACOD vs m-BNCOD in the treatment of stage II-IV diffuse
non-Hodgkin’s lymphomas. Haematologica 74:563-569, 1989.
26. Unterhalt M, Herrmann R, Tiemann M, et al: Prednimustine,
mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the
treatment of advanced low-grade non-Hodgkin’s lymphoma. Leukemia 10:836-843,
27. Takagi T, Sampi K, Sawada U, et al: A comparative study of
CHOP vs MEVP (mitoxantrone, etoposide, vindesine, prednisolone) therapy for
intermediate-grade and high-grade non-Hodgkin’s lymphoma: A prospective
randomized study. Int J Hematol 57:67-71, 1993.
28. Crossley RJ: Clinical safety and tolerance of mitoxantrone.
Semin Oncol 11:54-58, 1984.
29. Vorobiof DA, Terblanche AP, Falkson CI, et al:
Cyclophosphamide, mitoxantrone, vincristine, and prednisone in the treatment of
non-Hodgkin’s lymphoma. Oncology 45:378-379, 1988.
30. Vose J, Weisenburger D, Lynch J, et al: CNOP for diffuse
aggressive non-Hodgkin’s lymphoma: The Nebraska Lymphoma Study Group
experience. Leuk Lymphoma. In press.
31. Bjorkholm M, Osby E, Hagberg H, et al: Randomized trial of
r-metHu granulocyte colony-stimulating factor (G-CSF) as adjunct to CHOP or CNOP
treatment of elderly patients with aggressive non-Hodgkin’s lymphoma. Blood
94(suppl 1):599a, 1999.
32. Mazza P, Bocchia M, Zanchini R, et al: MN (N = Novantrone)
COP-B therapy on high and intermediate grade non-Hodgkin’s lymphoma: An
alternative to MA (A = adriamycin) COP-B? Haematologica 76:47-52, 1991.
33. Landys KE: Mitoxantrone in combination with prednimustine in
treatment of unfavorable non-Hodgkin’s lymphoma. Invest New Drugs 6:105-113,
34. Phillips J, Sherlaw-Johnson C, Davies J, et al: P-COMM-B
induction chemotherapy in intermediate- and high-grade non-Hodgkin’s lymphoma.
Leuk Lymphoma 18:137-143, 1995.
35. De Lena M, Ditonno P, Lorusso V, et al: CEOP-B alternated
with VIMB in intermediate-grade and high-grade non-Hodgkin’s lymphoma: A pilot
study. J Clin Oncol 13:953-960, 1995.
36. Ohnoshi T, Hayashi K, Ueno K, et al: Alternating
chemotherapy of CHOP-Bleo and POEM-Bleo for diffuse large-cell lymphoma: A
single-institutional study with a long-term follow-up. Int J Hematol 58:93-98,
37. Child JA, Simmons AV, Barnard DL, et al: Twin-track studies
of ifosfamide and mitoxantrone (I-M) in recurrent high-grade non-Hodgkin’s
lymphoma and Hodgkin’s disease. Yorkshire Regional Lymphoma and Central
Lymphoma Groups. Hematol Oncol 9:235-244, 1991.
38. Lorusso V, Paradiso A, Guida Mert, et al: Ifosfamide plus
mitoxantrone as salvage treatment in non-Hodgkin’s lymphomas. Am J Clin Oncol
39. Aydogdu I, Koc H, Ilhan O, et al: Administration of MINE
protocol in untreated patients with intermediate- and high-grade non-Hodgkin’s
lymphoma. Haematologia 28:207-213, 1997.
40. Cancela A, Corrado C, Cerutti I, et al: Sequential MINE/CANP
regimen in intermediate- and high-grade non Hodgkin’s lymphoma (IHNHL)
(abstract 1253). Proc Am Soc Clin Oncol 14:399, 1995.
41. Dincol D, Icli F, Karaoguz H, et al: Mesna/ifosfamide,
mitoxantrone, etoposide, bleomycin, vincristine, prednisone (MINE-BOP)
combination chemotherapy in the treatment of refractory and relapsed non-Hodgkin’s
lymphoma. Acta Oncol 34:937-940, 1995.
42. Rodriguez MA, Cabanillas FC, Velasquez W, et al: Results of
a salvage treatment program for relapsing lymphoma: MINE consolidated with
ESHAP. J Clin Oncol 13:1734-1741, 1995.
43. Romaguera JE, Rodriguez MA, Hagemeister FB, et al: A phase
II trial of oral etoposide with mitoxantrone and ifosfamide/mesna consolidated
with intravenous etoposide, methylprednisolone, high-dose arabinoside, and
cisplatin as salvage therapy for relapsing and/or refractory lymphomas. Invest
New Drugs 12:217-222, 1994.
44. Romaguera JE, Rodriguez MA, Hagemeister FB, et al: Phase II
study of paclitaxel in combination with mitoxantrone and ifosfamide/mesna for
patients with relapsed or refractory non-Hodgkin’s lymphoma after failure to
cytarabine/cisplatin combination. Invest New Drugs 17:187-192, 1999.
45. Romaguera JE, Hagemeister FB, McLaughlin P, et al:
Ninety-six-hour paclitaxel infusion with mitoxantrone and ifosfamide/mesna and
consolidation with ESHAP for refractory and relapsed non-Hodgkin’s lymphoma.
Leuk Lymphoma 32:97-106, 1998.
46. Buzzoni R, Colleoni M, Nelli P, et al: Results of a salvage
regimen in refractory or relapsed non-Hodgkin’s lymphoma. Leuk Lymphoma
47. Merk K, Idestrom K, Johansson B, et al: Mitoxantrone,
etoposide, cytarabine, and prednisone as salvage therapy for refractory
non-Hodgkin lymphoma (NHL) and alternated with CHOP in previously untreated
patients with NHL. Eur J Haematol 46:33-37, 1991.
48. Doorduijn JK, Spruit P, van Der Holt B, et al: Etoposide,
mitoxantrone and prednisone: A salvage regimen with low toxicity for refractory
or relapsed non-Hodgkin’s lymphoma. Haematologica 85:814-819, 2000.
49. Santini G, Contu A, Porcellini A, et al: Mitoxantrone alone
or in combination chemotherapy (VeMP) as second-line treatment in relapsed or
refractory poor-prognosis non-Hodgkin’s lymphoma. A report of the Non-Hodgkin’s
Lymphoma Cooperative Study Group (NHLCSG). Haematologica 76:485-490, 1991.
50. Cohen S, Caplan S, Shustik C, et al: MVP: Mitoxantrone,
VP-16, and prednisonean effective regimen for relapsed non-Hodgkin’s
lymphoma (NHL) (abstract 84). Proc Am Soc Clin Oncol 17:22a, 1998.
51. Ohnoshi T, Hayashi K, Ueoka H, et al: Salvage chemotherapy
for non-Hodgkin’s lymphoma with a combination of mitoxantrone, etoposide,
cisplatin, and prednisolone. Cancer Treat Rep 71:639-641, 1987.
52. Vitolo U, Orsucci L, Bertini M, et al: Mitoxantrone,
etoposide, cisplatin and dexamethasone (MEPD) as salvage chemotherapy in
resistant non-Hodgkin’s lymphoma. Haematologica 76:43-46, 1991.
53. Yuen A, Sikic B, Horning S: Phase II trial of ONCEP
chemotherapy in patients with relapsed non-Hodgkin’s lymphoma (NHL) (abstract
1226). Proc Am Soc Clin Oncol 14:392, 1995.
54. Yuen A, Breslin S, Sikic B, et al: A phase I/II trial of
ONCEP chemotherapy with the multidrug resistance (MDR) modulator PSC 833 in
patients with recurrent or refractory non-Hodgkin’s lymphoma (NHL) (abstract
48). Proc Am Soc Clin Oncol 17:13a, 1998.
55. Bellesi G, Rigacci L, Alterini R, et al: A new protocol (MiCEP)
for the treatment of intermediate or high-grade non-Hodgkin’s lymphoma in the
elderly. Leuk Lymphoma 20:475-480, 1996.
56. Zinzani PL, Bendandi M, Gherlinzoni F, et al: VNCOP-B
regimen in the treatment of high-grade non-Hodgkin’s lymphoma in the elderly.
Haematologica 78:378-382, 1993.
57. Sonneveld P, Michiels JJ: Full dose chemotherapy in elderly
patients with non-Hodgkin’s lymphoma: A feasibility study using a mitoxantrone
containing regimen. Br J Cancer 62:105-108, 1990.
58. Bessell EM, Coutts A, Fletcher J, et al: Non-Hodgkin’s
lymphoma in elderly patients: A phase II study of MCOP chemotherapy in patients
aged 70 years or over with intermediate- or high-grade histology. Eur J Cancer
59. Karduss A, Gomez R, Cuellar F, et al: Evaluation of CNOP in
patients over 60 years of age with non-Hodgkin’s lymphoma (abstract 1281).
Proc Am Soc Clin Oncol 14:406, 1995.
60. Zinzani PL, Bendandi M, Magagnoli M, et al:
Fludarabine-mitoxantrone combination-containing regimen in recurrent low-grade
non-Hodgkin’s lymphoma. Ann Oncol 8:379-383, 1997.
61. Lichtman S, Fusco D, Vinciguerra V, et al: Non-Hodgkin’s
lymphoma in the elderly. A pilot trial of thiotepa, Novantrone, Oncovin, and
prednisone (T-NOP) (abstract). Proc Am Soc Clin Oncol 11:380, 1993.
62. Merli F, Federico M, Avanzini P,: Weekly administration of
vincristine, cyclophosphamide, mitoxantrone and bleomycin (VEMB) in the
treatment of elderly aggressive non-Hodgkin’s lymphoma. Gruppo Italiano per lo
Studio dei Linfomi. Haematologica 83:217-221, 1998.
63. Sherwood G, Fredette R, Roberson J, et al: N-COPE: A
potentially curative regimen for the treatment of aggressive non-Hodgkin’s
lymphoma (NHL) in frail elderly patients (abstract 146). Proc Am Soc Clin Oncol
64. Tirelli U, Zagonel V, Errante D, et al: A prospective study
of a new combination chemotherapy regimen in patients older than 70 years with
unfavorable non-Hodgkin’s lymphoma. J Clin Oncol 10:228-236, 1992.
65. Yau JC, Germond C, Gluck S, et al: Mitoxantrone,
prednimustine, and vincristine for elderly patients with aggressive non-Hodgkin’s
lymphoma. Am J Hematol 59:156-160, 1998.
66. Zinzani PL, Storti S, Zaccaria A, et al: Elderly
aggressive-histology non-Hodgkin’s lymphoma: First-line VNCOP-B regimen
experience on 350 patients. Blood 94:33-38, 1999.
67. Goss P, Burkes R, Rudinskas L, et al: A phase II trial of
prednisone, oral etoposide, and novantrone (PEN) as initial treatment of
non-Hodgkin’s lymphoma in elderly patients. Leuk Lymphoma 18:145-152, 1995.
68. Salvagno L, Contu A, Bianco A, et al: A combination of
mitoxantrone, etoposide, and prednisone in elderly patients with non-Hodgkin’s
lymphoma. Ann Oncol 3:833-837, 1992.
69. Mainwaring PN, Cunningham D, Gregory W, et al: Mitoxantrone
is superior to doxorubicin in a multiagent weekly regimen for patients older
than 60 with high-grade lymphoma: Results of a BNLI randomized trial of
PAdriaCEBO vs PMitCEBO. Blood 97:2991-2997, 2001.
70. Velasquez W, Lew D, Miller T, et al: SWOG 95-01: A phase II
trial of a combination of fludarabine and mitoxantrone (FN) in untreated
advanced low grade lymphoma: An effective, well-tolerated therapy (abstract 27).
Proc Am Soc Clin Oncol 18:9a, 1999.
71. Zinzani P, Magagnoli M, Bendandi M, et al: Efficacy of
fludarabine and mitoxantrone (FN) combination regimen in untreated indolent
non-Hodgkin’s lymphomas. Ann Oncol 11:363-365, 2000.
72. Foussard C, Deconinck E, Desablens B, et al: A randomized
trial of fludarabine, mitoxantrone (FM) vs doxorubicin, cyclophosphamide,
vindesine, prednisone (CHEP) as first-line treatment in patients with advanced
low-grade non-Hodgkin lymphoma (LG-NHL): A multicenter study by GOELAMS group.
Blood 92(suppl 1):316b, 1998.
73. Tsimberidou AM, McLaughlin P, Younes A, et al: Randomized
comparison of fludarabine-novantrone-dexamethasone (FND) vs CHOD-BLEO/ESHAP/NOPP
(alternating triple therapy; ATT) in patients with stage IV indolent lymphoma.
Blood 96(suppl 1):508a, 2000.
74. McLaughlin P, Hagemeister FB, Swan F, et al: Phase I study
of the combination of fludarabine, mitoxantrone, and dexamethasone in low-grade
lymphoma. J Clin Oncol 12:575-579, 1994.
75. McLaughlin P, Hagemeister FB, Romaguera JE, et al:
Fludarabine, mitoxantrone, and dexamethasone: An effective new regimen for
indolent lymphoma. J Clin Oncol 14:1262-1268, 1996.
76. Zinzani PL, Brendandi M, Tura S: FMP regimen (fludarabine,
mitoxantrone, prednisone) as therapy in recurrent low-grade non-Hodgkin’s
lymphoma. Eur J Hematol 55:262-266, 1995.
77. Crawley C, Foran J, Gupta R, et al: A phase II study to
evaluate the combination of fludarabine, mitoxantrone, and dexamethasone (FMD)
in patients with follicular lymphoma. Ann Oncol 11:861-865, 2000.
78. Emmanouilides C, Rosen P, Rasti S, et al: Treatment of
indolent lymphoma with fludarabine/mitoxantrone combination: A phase II trial.
Hematol Oncol 16:107-116, 1998.
79. Saven A, Lee T, Kosty M, et al: Cladribine and mitoxantrone
dose escalation in indolent non-Hodgkin’s lymphoma. J Clin Oncol 14:2139-2144,
80. Robak T, Gora-Tybor J, Urbanska-Rys H, et al: Combination
regimen of 2-chlorodeoxyadenosine (cladribine), mitoxantrone, and dexamethasone
(CMD) in the treatment of refractory and recurrent low-grade non-Hodgkin’s
lymphoma. Leuk Lymphoma 32:359-363, 1999.
81. Rosso A, Pavlovsky S, Cappa C, et al: Cladribine (2-CdA),
mitoxantrone, dexamethasone, and G-CSF (CMD-G) in the treatment of relapsed or
refractory indolent non-Hodgkin lymphoma. Phase II study. Interim Analysis.
Blood 94(suppl 1):96a, 1999.
82. Rummel MJ, Chow KU, Karakas T, et al: Cladribine
(2-chlorodeoxyadenosine, 2-CdA) plus mitoxantrone in the treatment of
progressive advanced low-grade non-Hodgkin’s and mantle cell lymphomaspreliminary
results of a phase II study. Blood 94(suppl 1):660a, 1999.
83. Freund M, Wunsch-Zeddies S, Schäfers M, et al:
Prednimustine and mitoxantrone (PmM) in patients with low-grade malignant
non-Hodgkin’s lymphoma (NHL), chronic lymphocytic leukemia (CLL), and
prolymphocytic leukemia (PLL). Ann Hematol 64:83-87, 1992.
84. Bernard T, Johnson SA, Prentice AG, et al:
Mitoxantrone, chlorambucil, and prednisolone in the treatment of non-Hodgkin’s
lymphoma. Leuk Lymphoma 15:481-485, 1994.
85. Ben-Shahar M, Gepstein R, Haim N, et al: Phase III trial of
a combination of chlorambucil (L) and prednisone (P) with or without
mitoxantrone (M) in advanced low grade non-Hodgkin’s lymphoma (NHL) and CLL
(abstract 75). Proc Am Soc Clin Oncol 17:20a, 1998.
86. Jones L, Cotter FE, Lord D, et al: Phase II study of
mitoxantrone in combination with chlorambucil and prednisolone for relapsed and
refractory non-Hodgkin’s lymphoma. Hematol Oncol 8:41-45, 1990.
87. Haak HL, Gerrits WB, Wijermans PW, et al: Mitoxantrone,
teniposide, chlorambucil, and prednisone (MVLP) for relapsed non-Hodgkin’s
lymphoma. The impact of advanced age and performance status. Neth J Med
88. Chow KU, Rummel MJ, Weidmann E, et al: Induction of
apoptosis by 2-chloro-2´deoxyadenosine (2-CdA) alone and in combination with
other cytotoxic drugs: Synergistic effects on normal and neoplastic lymphocytes
by addition of doxorubicin and mitoxantrone. Leuk Lymphoma 36:559-567, 2000.
89. Gregory S, Venugopal P, Adler S, et al: A phase II study of
mitoxantrone and fludarabine followed by anti-CD20 monoclonal in the treatment
of patients with previously untreated low-grade non-Hodgkin’s lymphoma (LG-NHL).
Blood 96(suppl 1):732a, 2000.
90. Emmanouilides C, Rosen P, Telatar M, et al: Excellent
tolerance of rituximab when given after mitoxantrone/cyclophosphamide: An
effective and safe combination for indolent non-Hodgkin’s lymphoma. Clin
Lymphoma 1:146-151 (incl discussion), 2000.
91. Giraldo P, Pelegrin F, Palomera L, et al: Relapsed
follicular lymphoma. Response to fludarabine-mitoxantrone regimen and monoclonal
anti CD20 (rituximab). Blood 96(suppl 1):730a, 2000.
92. Joyce R, Krasner C, Tetreau J, et al: Rituximab and
ifosfamide, mitoxantrone, etoposide (RIME) with Neupogen support for CD 20+ NHL
prior to HDC-ASCT. Blood 96(suppl 1):186a, 2000.
93. Kersten MJ, Verduyn TJ, Reiss P, et al: Treatment of
AIDS-related non-Hodgkin’s lymphoma with chemotherapy (CNOP) and r-hu-G-CSF:
Clinical outcome and effect on HIV-1 viral load. Ann Oncol 9:1135-1138, 1998.
94. Tirelli U, Errante D, Spina M, et al: Second-line
chemotherapy in human immunodeficiency virus-related non-Hodgkin’s lymphoma:
Evidence of activity of a combination of etoposide, mitoxantrone, and
prednimustine in relapsed patients. Cancer 77:2127-2131, 1996.
95. Harrington W, Hurley J, Cabral L, et al: Phase II trial
comparing chemotherapy with and without antiretroviral therapy in the treatment
of AIDS associated large cell lymphoma (abstract 75). Proc Am Soc Clin Oncol
96. Aviles A, Halabe J: Improved prognosis in patients with
acquired immunodeficiency syndrome-related lymphoma. Cancer Biother Radiopharm
97. Attal M, Canal P, Schlaifer D, et al: Escalating dose of
mitoxantrone with high-dose cyclophosphamide, carmustine, and etoposide in
patients with refractory lymphoma undergoing autologous bone marrow
transplantation. J Clin Oncol 12:141-148, 1994.
98. Haas R, Moos M, Mohle R, et al: High-dose therapy with
peripheral blood progenitor cell transplantation in low-grade non-Hodgkin’s
lymphoma. Bone Marrow Transplant 17:149-155, 1996.
99. Martinelli G, Scalamogna R, Ghielmini M, et al: A novel
regimen of high- dose chemotherapy (HDCT) for first relapse follicular
non-Hodgkin lymphoma patients. Blood 96(suppl 1):797a, 2000.
100. Narayanasami U, Klekar A, Miller K, et al:
Melphalan/mitoxantrone preparative regimen for autologous stem cell
transplantation in patients with non-Hodgkin’s lymphoma and Hodgkin’s
disease: A single institution experience. Blood 96(suppl 1):385a, 2000.
101. Schenkein DP, Roitman D, Miller KB, et al: A phase II
multicenter trial of high-dose sequential chemotherapy and peripheral blood stem
cell transplantation as initial therapy for patients with high-risk non-Hodgkin’s
lymphoma. Biol Blood Marrow Transplant 3:210-216, 1997.
102. Ballestrero A, Clavio M, Ferrando F: High-dose chemotherapy
with tandem autologous transplantation as part of the initial therapy for
aggressive non-Hodgkin’s lymphoma. Int J Oncol 17:1007-1013, 2000.
103. Tarella C, Caracciolo D, Corradini P, et al: Long-term
follow-up of advanced-stage low-grade lymphoma patients treated upfront with
high-dose sequential chemotherapy and autograft. Leukemia 14:740-747, 2000.
104. Fitoussi O, Simon D, Brice P, et al: Tandem transplant of
peripheral blood stem cells for patients with poor-prognosis Hodgkin’s disease
or non-Hodgkin’s lymphoma. Bone Marrow Transplant 24:747-755, 1999.